FEATURED ARTICLES

• What 9 Years Of MDR Experience Is Changing About PMCF Planning

  Re-evaluate your compliance roadmap by exploring expert perspectives on navigating regulatory shifts, distinguishing core surveillance obligations, and building a defensible, value-driven clinical data strategy.

• UK Clinical Trial Regulations Reform

  UK trial regulations have been overhauled. Learn what faster approval pathways, stricter publication rules, and longer retention requirements mean for your operations.

• ICH E6(R3) Annex 2: Navigating GCP Requirements For Decentralized Trials

  Implementing decentralized components or real-world data requires proactive alignment with updated GCP standards for data access, remote consent, and multi-stream investigator oversight.

• Early-Stage Biotech's AI Advantage Is A Window That Closes

  FDA AI guidance won’t build your strategy for you. Learn how biotech teams can avoid retrofits and design smarter clinical AI from day one.

• Meeting The FDA's New Real-World Evidence Standards

  FDA guidance is reshaping RWE strategy. Sponsors that build interoperable, audit-ready RWD infrastructure now will be best positioned for faster, defensible submissions.

• Where PRO Strategy Goes Wrong

  PRO and COA strategy is now central to trial success. Organizations that capture meaningful patient experience data will gain stronger evidence and a regulatory advantage.

• Is The Industry Ready To Trust LLMs With Chart Review?

  See how LLM-powered extraction transforms unstructured medical records into compliant, audit-ready clinical data with machine-scale speed, human oversight, and regulatory-grade accuracy.

• The eCOA Iceberg

  Understand the true cost of eCOA deployment, beyond software licenses, to reduce protocol risk, avoid operational bottlenecks, and protect study timelines and data quality.

• Optimizing Data Capture From Protocol Design To Efficacy Endpoints

  The shift to digital trials favors the 11-point NRS over the traditional VAS to reduce data noise, improve elderly patient compliance, and ensure statistical power across mobile devices.

• Own Your Data, Accelerate Your Cure

  Move from passive donor to active innovator. Explore how patient communities are building their own research infrastructure and using AI to bypass traditional barriers to drug development.